<DOC>
	<DOCNO>NCT02194023</DOCNO>
	<brief_summary>In current study test hypothesis new 0.05 % Cetylpyridinium chloride ( CPC ) mouthrinse formulation contain 0.12 % 0.03 % chlorhexidine digluconate ( CHX ) : 1 ) yield similar well clinical result regard inhibition de novo plaque growth compare achieve already market 0.12 % CHX mouthrinse ( Perio-Aid Treatment without alcohol . Dentaid , Spain ) , 2 ) reduce side effect cause marketed 0.12 % CHX formula 3 ) mouthrinses negative microbiological effect , control total bacterial load .</brief_summary>
	<brief_title>Clinical Effects Two New Chlorhexidine Digluconate Formulations : 0.12 % 0.03 % .</brief_title>
	<detailed_description />
	<mesh_term>Dental Plaque</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<criteria>1830 year Good overall health without medical history medication could interfere study conduct . Minimum 6 teeth per quadrant . Absence probe depth ≥4mm . Allergy CHX CPC . Continuous use CHX oral antiseptic month prior study . Any adverse medical background longterm medication could affect gingival condition . Having take antibiotic previous three month . Moderate severe gingivitis ( bleed probe ≥ 40 % ) . 41 ( Van der Weijden et al . 1994 ) . Pregnancy breastfeed . Smokers 5 cigarette per day . Orthodontic appliance . Fixed removable prosthesis . Systemic diseases increase risk gingival disease ( diabetes mellitus , immunosuppression ) . Severe dental crowding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>chlorhexidine digluconate</keyword>
	<keyword>gingivitis</keyword>
	<keyword>cetylpyridinium chloride</keyword>
	<keyword>mouthrinse</keyword>
	<keyword>dental plaque</keyword>
	<keyword>de novo</keyword>
	<keyword>vivo</keyword>
</DOC>